Ottima azienda solida finanziariamente senza debiti a lungo e breve termine. Il FcF tende a diminuire nel tempo mentre aumentano i compensi per i vari membri del board che hanno uno skill in the game moderato.Read more
Corcept is betting big that its new cortisol medicines can grow beyond its current product, including potential uses in cancer and other hard-to-treat diseases. But delays with regulators, mixed trial results, or cheaper copycat competition could slow the story down and leave the company spending heavily before the payoff arrives.Read more
Corcept Therapeutics could be on the verge of expanding beyond its current lead medicine as more doctors screen for the disease it treats and new drugs move closer to approval. But the story has a catch: the business still leans heavily on one product while legal fights, approval delays, and drug pricing pressure could slow the path to wider growth.Read more
Catalysts About Corcept Therapeutics Corcept Therapeutics develops selective cortisol modulators to treat serious endocrine, metabolic and oncologic diseases. What are the underlying business or industry changes driving this perspective?Read more
No trending discussion available.
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig’s disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
